The use of HDAC inhibitors (HDACi) has proven to be an effective strategy in anticancer treatment, both as single agents and in combination therapies targeting various types of cancer, including pancreatic, solid tumors, and hematologic malignancies. The gene discussed is HDAC9; the disease is hematologic disorder.